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Abstract 1 
Background: Lipids are increasingly involved in cardiovascular risk prediction as potential pro-2 
arrhythmic influencers. However, knowledge is limited about the specific mechanisms connecting 3 
lipid alterations with atrial conduction. 4 
Methods: To shed light on this issue, we conducted a broad assessment of 151 sphingo- and 5 
phospholipids, measured using mass-spectrometry, for association with atrial conduction, 6 
measured by P wave duration (PWD) from standard electrocardiograms, in the Microisolates in 7 
South Tyrol study (n=839). Causal pathways involving lipidomics, BMI, and PWD were assessed 8 
using two-sample Mendelian randomization analyses based on published genome-wide 9 
association studies of lipidomics (n=4034) and BMI (n=734,481), and genetic association analysis 10 
of PWD in 5 population-based studies (n=24,236). 11 
Results: We identified an association with relative phosphatidylcholine 38:3 (%PC 38:3) 12 
concentration, which was replicated in the Orkney Complex Disease Study (n=951), with a pooled 13 
association across studies of 2.59 (95% confidence interval: 1.3, 3.9; P-value=1.1×10-4) ms PWD 14 
per mol% increase. While being independent of cholesterol, triglycerides, and glucose levels, the 15 
%PC 38:3 - PWD association was mediated by body mass index (BMI). Results supported a causal 16 
effect of BMI on both PWD (P-value=8.3×10-5) and %PC 38:3 (P-value=0.014). 17 
Conclusions: Increased %PC 38:3 levels are consistently associated with longer PWD, partly due 18 
to the confounding effect of BMI. The causal effect of BMI on PWD reinforces evidence of BMI’s 19 
involvement into atrial electrical activity.  20 
 21 
Key words: Lipidomics; P wave duration; body mass index; Mendelian randomization; mediation 22 
analysis; atrial conduction; phosphatidylcholine 38:3 23 
 24 
 25 
 26 
 27 
 28 
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Introduction 1 
P wave indices obtained from standard electrocardiograms are generally accepted as a reliable non-2 
invasive marker of atrial conduction1. Among them, increased P wave duration (PWD) has been 3 
associated with cardiovascular and all-cause mortality and alterations in PWD were established as 4 
an intermediate phenotype for atrial fibrillation (AF)1, which affects >10 million European 5 
citizens2. The identification of biological pathways underlying PWD regulation is important to 6 
define the physiological context of PWD within cardiovascular health. 7 
Lipids measured using mass spectrometry are promising biomarkers for cardiovascular risk 8 
prediction3,4. Additionally, given the potential pro-arrhythmic effect of certain species, like in the 9 
context of ischemic heart disease, lipids are increasingly being considered as target molecules for 10 
developing new anti-arrhythmic drugs5. We previously measured 151 phospho- and sphingolipids 11 
in the context of the EUROSPAN consortium to conduct genome-wide association studies 12 
(GWAS) aimed at uncovering genetic loci involved in lipid regulation6,7. Lipids were assessed 13 
within 6 classes which included 24 sphingomyelins (SPM), 57 phosphatidylcholines (PC), 27 14 
phosphatidylehanolamines (PE), 19 PE-based plasmalogens (PLPE), 15 lysophosphatidylcholines 15 
(LPC), and 9 ceramides (CER). The EUROSPAN GWAS identified more than thirty loci 16 
associated with individuals’ lipidomic profiles and, to date, are still amongst the largest studies in 17 
the field. 18 
To investigate whether and how lipidomics is involved in atrial conduction, we assessed 19 
whether any of such 151 phospho- and sphingolipids was associated with PWD, implementing a 20 
discovery-replication design that involved two independent population-based studies. Among the 21 
analyzed lipids, the relative concentration of PC 38:3 was strongly associated with PWD, 22 
independently of several cardio-metabolic risk factors, except for the body mass index (BMI). 23 
After investigating the mediating role of BMI, we eventually used Mendelian randomization (MR) 24 
analysis to assess causality between PC 38:3, BMI, and atrial conduction using summary statistics 25 
from the largest GWAS on lipidomics and BMI, available to date. 26 
 27 
Methods 28 
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In accordance with Transparency and Openness Promotion Guidelines, the data that are not already 1 
included in the Data Supplement and the analytical workflow will be made available to other 2 
researchers for purposes of reproducing the results or replicating the procedure. All contributing 3 
studies received approval by their local ethics committees. All participants gave written informed 4 
consent. The full methods are available in the Supplemental Material. 5 
 6 
Results 7 
Lipidomics association analysis 8 
By following the study workflow presented in Figure 1, we first carried out an observational 9 
analysis in the Microisolates in South Tyrol (MICROS) study8,9 to assess whether any out of 151 10 
measured lipids was associated with PWD in the general population. Results were tested for 11 
independent replication in the Orkney Complex Disease Study (ORCADES)10. Table 1 outlines 12 
discovery and replication study’s characteristics. MICROS participants were on average 44 years 13 
old (SD=16.1), had mean PWD=102.8 (SD=14.3) ms, 52% were females, 4.5% under lipid-14 
lowering therapy (LLT), and 12.3% under anti-hypertensive treatment (AHT). ORCADES’s 15 
participants were older (mean age=53, SD=15.1) and, consistently, more were under LLT (12.0%) 16 
or AHT (20.5%). 17 
Distributions of the 151 lipids in the MICROS study are summarized in Supplemental Table 1 18 
and their pairwise correlations depicted in Supplemental Figure 1. Eighteen lipids were 19 
associated with PWD (P-value≤0.05), including 6 PEs, 6 PCs, 3 LPCs, 2 PLPEs, and 1 SPM 20 
(Table 2). Replication in the ORCADES, tested at the one-sided level of 5.6×10-3 accounting for 21 
the 18 lipids submitted to validation, confirmed the association of PWD with %PC 38:3 (one-sided 22 
P-value=1.9×10–3, Table 2). The association coefficient was very similar between MICROS 23 
(b=2.27 ms per mol% increase, SE=0.86) and ORCADES (b=3.08, SE=1.06; Figure 2A), with a 24 
pooled estimate β=2.59 (SE=0.67, P-value=1.1×10–4; Table 2). In terms of absolute 25 
concentrations, 1 µM PC 38:3 increase was associated with a PWD increase of 0.06 ms (SE=0.02) 26 
in MICROS, and 0.07 ms (SE=0.04) in ORCADES, with a pooled estimate of 0.06 ms (SE=0.02, 27 
P-value=1.9×10–3). 28 
 29 
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Sensitivity analysis 1 
Results were unchanged when excluding subjects under LLT, AHT, or with a %PC 38:3 level 2 
larger than the 99th percentile from both the discovery and replication analyses (Supplemental 3 
Table 2). We then assessed heuristically whether the %PC 38:3 - PWD association coefficient 4 
changed when adjusting for the cardio-metabolic factors listed in Table 3. This was not the case 5 
for any factor, except for BMI: BMI adjustment attenuated the %PC 38:3 - PWD association to 6 
about half of the magnitude, losing significance in both MICROS (P-value=0.131) and ORCADES 7 
(P-value=0.188, Table 3). When fitting a multivariable model that included all quantitative cardio-8 
metabolic risk factors together, results where similar to when adjusting for BMI only (Table 3). 9 
This result suggested that BMI is the only one, among the considered cardio-metabolic factors, 10 
that may have a role in the %PC 38:3 – PWD relationship, and that BMI’s role is independent of 11 
that of the other factors. This motivated additional mediation and MR analyses to investigate 12 
possible causal pathways involving %PC 38:3, BMI, and PWD. 13 
 14 
Mediation analysis 15 
To assess whether BMI qualified as a mediator between %PC 38:3 and PWD, we conducted 16 
mediation analysis in MICROS and ORCADES separately, pooling the results via inverse-17 
variance-weighted (IVW) meta-analysis (Supplemental Methods). BMI satisfied all conditions 18 
of complete mediation between %PC 38:3 and PWD in both MICROS and ORCADES (Table 4, 19 
upper part): %PC 38:3 was associated with BMI (P-value=1.0×10-33 and 8.5×10-36 in MICROS 20 
and ORCADES, respectively); PWD was associated with BMI when controlling for %PC 38:3 (P-21 
value=0.016 and 2.0×10-4 in MICROS and ORCADES, respectively); and PWD was not 22 
associated with %PC 38:3 when controlling for BMI neither in MICROS (P-value=0.131) nor in 23 
ORCADES (P-value=0.188), except showing significance in the meta-analysis (P-value=0.045). 24 
Results were confirmed by the Sobel test and bootstrap analysis (Table 4, upper part). 25 
When testing whether %PC 38:3 could be mediate the BMI-PWD relationship, the indirect 26 
effect of BMI on %PC 38:3 was significant in the meta-analysis (P-value=0.012) but not in any of 27 
the two studies (Table 4, lower part). BMI explained 28% of %PC 38:3 variability. 28 
 29 
Mendelian randomization analyses 30 
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Mediation analysis results led us hypothesizing that the causal pathway could be either (1) %PC 1 
38:3  BMI  PWD or (2) BMI  %PC 38:3  PWD. Therefore, we performed two-sample 2 
MR analyses to investigate the respective causal effects under the two scenarios. SNPs for use as 3 
instrumental variables (IVs) for MR analyses involving %PC 38:3 were identified from a GWAS 4 
of %PC 38:3 concentrations from the EUROSPAN consortium6,7 (n=4034). To identify SNPs for 5 
use as IVs in MR analyses involving BMI and to obtain estimates of the association between %PC 6 
38:3-associated SNPs and BMI, we interrogated summary data from a recent meta-analysis of 7 
GWAS of BMI from the Genetic Investigation of Anthropometric traits (GIANT) Consortium and 8 
UK Biobank (UKB) involving an average of 734,481 European-ancestry individuals11. SNP effect 9 
estimates on PWD were obtained by analyzing 24,236 general population individuals from the 10 
Cooperative Health Research in South Tyrol (CHRIS) study12,  Prevention of REnal and Vascular 11 
ENd-stage Disease (PREVEND)13,14, Lifelines Cohort Study (Lifelines)14,15, and the Study of 12 
Health in Pomerania (SHIP)16 and SHIP-TREND16 (Supplemental Methods). Characteristics of 13 
study participants (all of European ancestry) are given in Supplemental Table 3. 14 
For the first hypothesized causal pathway (Figure 3A), we identified 3 valid IVs for %PC 38:3 15 
from the EUROSPAN GWAS7: rs3198697, a missense variant of unknown clinical significance 16 
in the PDXDC1 gene (F=100); rs968567 in FADS2 (F=25); and rs7192552 also in PDXDC1 17 
(F=100) but independent of rs3198697 (LD r2=0.008). All variants were genome-wide significant, 18 
qualified as strong instruments, and altogether explained 7% of %PC 38:3 variability 19 
(Supplemental Table 4). When pooling together the individual SNP MR results, we observed a 20 
non-significant positive effect of %PC 38:3 on BMI (P-value=0.057) with possible pleiotropy 21 
(I2=69%, Q test P-value=0.048; Figure 3A). To assess the causal effect of BMI on PWD, IV 22 
selection from the GIANT+UKB meta-analysis started with all 941 genome-wide significant 23 
variants, which explained 6% of BMI variance11. From these, 842 SNPs qualified as strong 24 
instruments (F>10). Among them, starting from the SNP with the largest F value, we identified 25 
187 independent (LD r2<0.01) SNPs (Supplemental Table 5): these SNPs explained 2.9% of BMI 26 
variance, which is lower than the reported one, due to the more stringent selection criteria used for 27 
this MR study. Effect estimates of the 187 SNPs on PWD obtained from the meta-analysis of 28 
association results from CHRIS, PREVEND, Lifelines, SHIP, and SHIP-TREND studies 29 
(n=24,236) are shown in Supplemental Table 5. The combined MR estimate across all SNPs 30 
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showed a positive causal effect of BMI on PWD (P-value=1.1×10-3), with no pleiotropy (I2=0; Q 1 
test P-value=0.876; Figure 3A). 2 
Next, we assessed the alternative causal pathway going from BMI to PWD through %PC 3 
38:3 (Figure 3B). To assess the causal effect of BMI on %PC 38:3, we used the same 187 IVs for 4 
BMI described above and looked up the results in the EUROSPAN %PC 38:3 GWAS meta-5 
analysis. Results supported a possible causal effect of BMI on %PC 38:3 (P-value=0.014) with 6 
limited evidence of pleiotropy (I2=27%; Q test P-value=1×10-3; Figure 3B; Supplemental Table 7 
6). To assess the causal effect of %PC 38:3 on PWD, we tested the association of two of the SNPs 8 
identified in the EUROSPAN %PC 38:3 GWAS and PWD in the 24,236 individuals from the five 9 
studies mentioned above. SNP rs7192552 was not contained in the 1000G dataset used for 10 
genotype imputation by the five studies. There was no support for a causal effect of %PC 38:3 on 11 
PWD (P-value=0.251; Figure 3B; Supplemental Table 7). 12 
The results of this last analysis suggest a third possible scenario where the causal effect of 13 
BMI on both %PC 38:3 and PWD, together with no causal effect of %PC 38:3 on PWD, may 14 
indicate that BMI is a confounder of the %PC 38:3-PWD association (Figure 3C). 15 
Robustness of MR results was assessed in two ways. First, we performed post-hoc power 16 
calculations. Results show that our analysis would have had sufficient power to detect a causal 17 
effect of %PC 38:3 on BMI only if the causal effect had been close to the value of the association 18 
coefficient (Supplemental Figure 2A), that is, if the observed association was entirely due to the 19 
cause-effect relationship. Indeed, the MR effect of %PC 38:3 on BMI was ~5 times larger than the 20 
association estimate, achieving a theoretical 100% power. However, this value seems more likely 21 
to result from a small sample bias problem (small GWAS sample size; small number of 22 
instruments) and the causal effect estimate doesn’t look realistic. On the other hand, our analyses 23 
were well-powered to assess a causal effect of BMI on PWD: power was already approaching 24 
100% for causal effect estimates that were ~1/10th of the estimated association coefficient: the 25 
observed causal effect estimate fell in the 100% power range (Supplementary Figure 2B). Likely 26 
due to the very small association coefficient between BMI and %PC 38:3, our analysis was 27 
underpowered to assess causal effects of BMI on %PC 38:3 (Supplementary Figure 2C). Finally, 28 
our analysis was also underpowered to detect a causal effect of %PC 38:3 on PWD (the power for 29 
the observed MR estimate of 0.795 was 0.06; Supplemental Figure 2D). 30 
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Second, we re-analyzed the data using alternative two-sample MR methods such as the 1 
MR-Egger regression17 and MR-PRESSO18, which are more robust to pleiotropy (Supplemental 2 
Table 8). Being based on linear regression, they couldn’t be applied to the %PC 38:3 - PWD MR 3 
analysis as only two IVs were available. For the BMI - %PC 38:3 MR analysis, MR-PRESSO 4 
confirmed the IVW result with very similar effect estimate (effect=1.2×10–3, P-value=0.025). In 5 
addition, MR-Egger analysis didn’t reject the hypothesis of absence of pleiotropy (intercept P-6 
value=0.557), further supporting the validity of the IVW estimate. For the BMI-PWD MR analysis, 7 
results of the IVW were strong as they were based on several instruments and had an I2=0 8 
indicating no horizontal pleiotropy: in these cases, the IVW estimator is more reliable than 9 
alternative estimators. Finally, the MR-PRESSO couldn’t be applied to the %PC 38:3 - BMI MR 10 
either, as the number of instruments didn’t exceed the number of parameters to be estimated in the 11 
model18. MR-Egger results appeared unreliable, because of the low number of instruments, a 50% 12 
estimated bias, and a Q ratio of 0.1, indicating the IVW estimator as more reliable even despite 13 
large I2. 14 
 15 
Discussion 16 
After screening 151 sphingo- and phospholipids for association with atrial conduction in the 17 
general population, our study identified that the relative concentration of phosphatidylcholine 38:3 18 
was robustly associated with the duration of the electrocardiographic P wave. This association, 19 
reported here for the first time, was independent of cholesterol, triglycerides, and glycemic levels, 20 
but it was fully mediated by BMI. Additional investigations showed that BMI is causally 21 
associated with PWD in the general population, and that the %PC 38:3 - PWD association likely 22 
reflects BMI’s confounding role. 23 
Phosphatidylcholines (PC) are a class of glycerophospholipids, which are important 24 
components of biological membranes and play a fundamental role in metabolism and signaling. 25 
PC 38:3 is a combination of several isomers containing fatty acids of varying lengths and saturation 26 
attached at the C-1 and C-2 positions. Using the Lipid Maps database19, we annotated 19 different 27 
potential PC 38:3 isomers. Based on the fatty acid composition of PC species in plasma20, two 28 
isomers are likely to be the most abundant species in the analyzed samples, namely the PC(18:2(n-29 
6)/20:1(n-9)) and PC(20:3(n-6)/18:0), which contain the two omega-6 fatty acids, linoleic acid 30 
11 
 
(LA) (18:2(n-6)) and dihomo-γ-linolenic acid (DGLA) (20:3(n-6)). In mammals, DGLA can be 1 
incorporated into cellular PCs.  2 
Despite strong association, our analyses didn’t show evidence of a causal link between 3 
%PC 38:3 and PWD, advocating for the confounding role of BMI (Figure 3C). This observation 4 
would be consistent with all our findings: BMI was causally associated with both %PC 38:3 and 5 
PWD; the %PC 38:3 - PWD association faded away when adjusting for BMI; and no causal link 6 
has been proven from %PC 38:3 to PWD. This model would suggest that increased BMI levels 7 
independently cause higher circulating %PC 38:3 levels and prolonged PWD, so that the observed 8 
%PC 38:3 - PWD association is just the reflection of the joint increase due to BMI. This would 9 
also explain why the association of %PC 38:3 with PWD was independent of other cardio-10 
metabolic markers. The results would also be consistent with previously observed association of 11 
higher PC 38:3 levels with cardiovascular disease risk3 but not AF incidence21.  12 
The causal effect of BMI on PWD was supported by a highly powered analysis with no 13 
evidence of pleiotropy. The causal effect of BMI on %PC 38:3 suffered of lack of power, which 14 
suggests careful interpretation. However, while not being absent, the between-instrument 15 
heterogeneity was small, giving limited room to possible pleiotropy, and the two alternative 16 
estimators, IVW and MR-PRESSO, showed very similar effect estimates, which were significant 17 
in both cases. On the other hand, the opposite causal effect of %PC 38:3 on BMI would receive 18 
even less support from the data: the MR analysis was underpowered and based on a limited number 19 
of IVs for which absence of horizontal pleiotropy could not be guaranteed. 20 
Association between PC 38:3 and BMI was reported previously22. Our results of a causal 21 
effect of BMI on %PC 38:3 might appear in contrast with a previous study that did not identify a 22 
causal link between BMI and phosphatidylcholines as a whole, even though the specific 23 
metabolites were not investigated23. For BMI to affect %PC 38:3 blood levels, one may 24 
hypothesize that fat (PC 38:3) is mobilized from adipocytes. This would be inconsistent with the 25 
fact that adipocytes release free fatty acids, immediately bound by serum albumin, and not PCs. 26 
However, it is possible that higher BMI levels could globally and indirectly affect %PC 38:3 levels 27 
through multiple signaling pathways: for instance, free fatty acids released from adipocytes might 28 
be used to synthesize PCs. Because PC 38:3 can contain either DGLA or LA, the latter entering 29 
human metabolism through diet only, a causal effect of PC 38:3 on BMI might look more plausible, 30 
12 
 
as such a model would be supported by established lipid metabolism physiology24. However, our 1 
data do not support this result. 2 
The causal association between BMI and PWD adds to previous literature showing 3 
association between obesity and longer PWD25 and positive association between BMI and PWD 4 
in population-based studies26.27. Our unconfounded MR analyses add that BMI is causally 5 
associated with PWD also in general population individuals, who were generally healthy and 6 
unselected for any disease. The causal mechanisms are probably multiple and the contrasting 7 
evidence of BMI being28 or not29 involved in the relationship between pericardial fat and PWD in 8 
the general population suggests that additional studies with deeply assessed clinical and molecular 9 
phenotypes are needed to disentangle the mechanisms of action of BMI on PWD. Our results recall 10 
recent evidence of a causal relationship between BMI and incident AF30. Together with the 11 
observation that prolonged PWD was associated with AF recurrence following cardioversion, AF 12 
following cardiothoracic surgery, and transition from paroxysmal to permanent AF26, our 13 
additional evidence of higher BMI causing prolonged PWD calls for the need to conduct a 14 
comprehensive study of the overall causal cascade involving BMI, PWD, and (incident) AF at the 15 
general population level. 16 
One strength of our study was the unbiased analysis of a large number of lipids and the 17 
replication of the main finding in a study population which was very different from the one used 18 
for discovery. MICROS8,9 and ORCADES10 were carried out in very localized contexts and 19 
different environments (the Tyrolean Alps and the Orkney Islands north of Scotland, respectively), 20 
on populations with very different cultural and life style background, leading to different health 21 
characteristics. The older age of ORCADES participants led to a longer average PWD as compared 22 
to their South Tyrolean counterparts. Despite those differences, the association coefficients 23 
between %PC 38:3 and PWD were remarkably similar. Very similar was also the attenuation of 24 
such an association due to the BMI adjustment, leading to similar results in the mediation analysis. 25 
A second strength was the standardization of the lipidomics panel across the two studies: by joining 26 
the EUROSPAN consortium6,7, MICROS and ORCADES had lipidomics measured in the same 27 
laboratory, at the same time, and with the same method, even if on different matrixes. A third 28 
strength is the very large sample size of the GIANT+UKB meta-analysis11 guaranteeing unbiased 29 
estimates of the causal effects of BMI on PWD and %PC 38:3. Finally, as a prerequisite of any 30 
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two-sample MR study, all studies involved were from European ancestry comparable populations 1 
with similar age distribution and from mainly population-based studies. 2 
Some limitations could not be avoided. One aspect of concern might be the liberal 3 
significance threshold used in the discovery stage, which might have led to a high risk of type I 4 
error. We could have attained a larger sample size and set a lower significance threshold by 5 
combining MICROS and ORCADES into a more powerful single-stage design31. Should we have 6 
adopted such an approach, the identification of the %PC 38:3 - PWD association would have been 7 
successful as the P-value of the meta-analysis result was 1.1×10–4: this is lower than a Bonferroni-8 
adjusted limit of 0.05/151, that is, if we had conservatively considered all 151 lipids independent 9 
from each other. However, such a choice would have deprived us from the possibility to replicate 10 
our findings in an independent study, raising questions on the repeatability of the results. Instead, 11 
we preferred to use a discovery-replication scheme, which allowed us to verify the presence of the 12 
association in two very different studies and, at the same time, to assess the consistency of the 13 
effect estimates across studies. Such a consistency was observed at all levels: association, 14 
sensitivity, and mediation analyses. This aspect is remarkable and in our opinion is valuable at 15 
least as much, if not more, than the statistical significance in itself32. In any case, further 16 
confirmation of this result is warranted by subsequent studies. Another limitation is that, in 17 
MICROS, lipid-lowering and anti-hypertensive therapies could only be assessed as self-reported 18 
information during standardized interviews. This might have prevented our sensitivity analyses 19 
from observing altering effects of total-, HDL-, and LDL-cholesterol and triglycerides on the %PC 20 
38:3 - PWD association. The absence of data on waist, hip and their ratio in the MICROS study 21 
prevented us to assess whether measures of fat distribution might also mediate the %PC 38:3 - 22 
PWD association. Further limitations concern the two-sample MR analyses. Sample overlap was 23 
between 0.5% and 2.7% of the combined exposure and outcome study sample size (Supplemental 24 
Table 7): as long as the IVs are strong, as in our case, such a small overlap should not bias the 25 
results33. A limitation of MR analyses involving %PC 38:3 as an exposure was that all three IVs 26 
might fully or in part violate the key assumption of absence of horizontal pleiotropy. The rs968567 27 
is associated with FADS2 and FADS1 gene expression34 and in strong LD with SNPs previously 28 
associated with PWD15. FADS2 desaturates linoleic and alpha-linolenic essential fatty acids. This 29 
is the first step of PUFA metabolism, and also the rate-limiting, because other lipids are generated 30 
following FADS2 activation. This is consistent with the observed associations of rs968567 with 31 
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PUFA levels35,36, and with a vertical pleiotropy scenario, under which the instrument would still 1 
be valid. This is equally true for FADS1 expression, acting immediately downstream FADS2. 2 
However, because rs968567 is also associated with inflammatory diseases37,38, it is not possible to 3 
rule out alternative pathways from gene to atrial conduction, consistent with a possibly imbalanced 4 
horizontal pleiotropy scenario. Pleiotropy analysis is even more challenging for the NPIPA2-5 
MYH11 locus, containing rs3198697 and rs7192552: despite being poorly characterized, the region 6 
has been associated with lipid phenotypes by several GWAS35,36,39,40, 41 thus making both vertical 7 
and horizontal pleiotropy two equally possible scenarios. 8 
 9 
Conclusions 10 
Increased levels of %PC 38:3 are consistently associated with longer PWD, reflecting the 11 
confounding role of BMI, which causally determines both. Given that both an increased BMI and 12 
a prolonged PWD are risk factors for AF, our results call further studies to assess whether a 13 
prolonged P wave duration is an intermediate causal step between increased body mass and AF. 14 
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TABLES 1 
Table 1. Characteristics of the MICROS (discovery) and ORCADES (replication) study 2 
samples. 3 
 
 
MICROS ORCADES 
Demographic characteristics Sample size 839 951 
 Age, mean(SD) 44(16.1) 53(15.1) 
 Female, N(%) 435(52) 535(56) 
    
Atrial depolarization PWD, ms, mean(SD) 102.8(14.3) 110.1(18.1) 
    
Cardio-metabolic health BMI, kg/m2, mean(SD) 25.4(4.6) 27.7(4.9) 
 LDL, mg/dL, mean(SD) 135.4(42.2) 138.6(42.5) 
 HDL, mg/dL, mean(SD)  65.1(14.5) 64.8(15.5) 
 TG, mg/dL, mean(SD) 126.6(96.3) 120.8(79.3) 
 TC, mg/dL, mean(SD) 226.4(46.1) 225.2(46.6) 
 SBP, mmHg, mean(SD) 132.3(19.9) 130.3(18.8) 
 DBP, mmHg, mean(SD) 79.5(10.8) 75.9(9.8) 
 FGlu, mmol, mean(SD) 4.7(0.93) 5.4(1.02) 
 DM, N(%) 27(3.2) 38(4.0) 
    
Medications LLT, N(%) 38(4.5) 113(12.0) 
 AHT, N(%) 103(12.3) 195(20.5) 
    
Absolute lipidomic concentrations SPM  24.55(33.60) 19.79(28.49) 
µM, mean(SD) PC  44.18(104.90) 33.96(78.88) 
 PE 1.41(1.94) 0.95(1.23) 
 PLPE 5.83(7.11) 4.18(4.93) 
 LPC 27.01(59.71) 15.47(31.87) 
 CER 1.16(1.09) 0.92(0.80) 
    
Relative lipidomic concentrations %SPM  0.04(0.06) 0.04(0.06) 
mol%, mean(SD) %PC  0.02(0.04) 0.02(0.04) 
 %PE 0.04(0.05) 0.04(0.05) 
 %PLPE 0.10(0.12) 0.10(0.12) 
 %LPC 0.07(0.14) 0.07(0.15) 
 %CER 0.13(0.11) 0.13(0.12) 
Abbreviations: SD = Standard deviation; PWD = P wave duration; AF = Atrial fibrillation; BMI = Body mass index; 4 
LDL = Low-density lipoprotein cholesterol; HDL = High-density lipoprotein cholesterol; TG = Triglycerides; TC = 5 
Total cholesterol; SBP = Systolic blood pressure; DBP = Diastolic blood pressure; FGlu = Fasting glucose; DM = 6 
Diabetes mellitus; LLT = lipid-lowering therapy; AHT = anti-hypertensive treatment; SPM = Sphingomyelins; PC = 7 
Phosphatidylcholines; PE = Phosphatidylethanolamines; PLPE = PE-based plasmalogens; LPC = 8 
Lysophosphatidylcholines; CER = Ceramides. 9 
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Table 2. Association analysis of PWD against relative lipidomic concentrations. The 18 lipids 1 
associated with PWD with P-value≤0.05 in the discovery study, their replication, and discovery-2 
replication meta-analysis. 3 
Lipid 
Discovery: MICROS Replication: ORCADES Meta-analysis 
b(SE) 
Two-
sided 
P-value b(SE) 
One-sided 
P-value b(SE) 
Two-sided 
P-value I
2% 
%PE 36:3 -1.25(0.40) 1.8×10-3 -0.81(0.53) 0.063 -1.09(0.32) 6.4×10-4 0 
%PE 34:2 -0.57(0.18) 2.1×10-3 -0.23(0.22) 0.148 -0.42(0.14) 2.5×10-3 30 
%PE 38:4 0.55(0.19) 3.0×10-3 0.07(0.20) 0.361 0.33(0.14) 0.016 67 
%PE 40:6 1.05(0.37) 4.6×10-3 0.35(0.28) 0.109 0.61(0.22) 6.9×10-3 56 
%PLPE 16:0/18:2 -1.26(0.46) 6.5×10-3 -0.68(0.52) 0.097 -1.00(0.35) 3.8×10-3 0 
%PC 30:1 -16.32(6.01) 6.7×10-3 -1.50(9.47) 0.437 -12.06(5.08) 0.017 43 
%PE 40:5 3.91(1.47) 7.9×10-3 0.90(1.67) 0.294 2.60(1.11) 0.019 45 
%PC 38:3 2.27(0.86) 8.5×10-3 3.08(1.06) 1.9×10-3 2.59(0.67) 1.1×10-4 0 
%PE 38:3 3.00(1.20) 0.013 2.25(1.58) 0.078 2.73(0.96) 4.4×10-3 0 
%PC 38:4 0.98(0.41) 0.016 0.53(0.46) 0.125 0.80(0.30) 0.103 0 
%PLPE 18:0/18:2 -0.65(0.29) 0.024 -0.51(0.31) 0.051 -0.58(0.21) 5.7×10-3 0 
%PC 34:2 -0.37(0.17) 0.025 -0.25(0.19) 0.093 -0.32(0.12) 0.010 0 
%LPC 20:3 6.10(2.89) 0.034 0.85(2.46) 0.366 3.06(1.88) 0.102 48 
%LPC 18:0 0.45(0.22) 0.042 0.59(0.26) 0.012 0.51(0.17) 2.7×10-3 0 
%PC 34:3 -6.84(3.41) 0.045 -1.33(3.01) 0.329 -3.75(2.25) 0.097 32 
%PC 40:6 3.06(1.53) 0.045 1.53(1.11) 0.083 2.06(0.90) 0.022 0 
%LPC 18:3 -16.49(8.26) 0.046 -3.87(5.91) 0.256 -8.14(4.81) 0.090 35 
%SPM 18:0 1.39(0.71) 0.049 1.14(0.78) 0.072 1.28(0.53) 0.015 0 
Symbols/abbreviations: b, estimate of the %PC 38:3-PWD association coefficient β expressing the PWD change in 4 
ms per 1 mol% increase of the relative lipid concentration; SE, standard error. 5 
Boldface highlights the results for %PC 38:3, whose association with PWD in the replication stage was robust to the 6 
Bonferroni-corrected significance level of 5.6×10-3 (see Methods in the Supplemental Material). 7 
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Table 3. Analysis of potential confounders of the %PC 38:3-PWD relationship: reported are the 1 
estimated association coefficients between %PC 38:3 and PWD (b, PWD change in ms per 1 mol% PC 2 
38:3 increase) and their standard errors (SE) when including the listed variables one at a time in the LMM. 3 
Potential 
confounder 
MICROS ORCADES Meta-analysis† 
b(SE) P-value b(SE) P-value b(SE) P-value 
BMI 1.41(0.93) 0.131 1.50(1.14) 0.188 1.45(0.72) 0.045 
LDL 2.13(0.93) 0.022 2.80(1.11) 0.012 2.41(0.71) 7.4×10-4 
HDL 2.25(0.90) 0.013 2.60(1.12) 0.020 2.39(0.70) 6.7×10-4 
TG 2.16(0.89) 0.015 2.92(1.11) 0.009 2.45(0.69) 4.0×10-4 
TC 2.11(0.88) 0.017 3.04(1.08) 5.0×10-3 2.48(0.68) 2.8×10-4 
DBP 1.91(0.87) 0.028 2.86(1.07) 7.5×10-3 2.29(0.67) 7.0×10-4 
SBP 1.99(0.87) 0.022 3.01(1.07) 5.0×10-3 2.40(0.68) 3.9×10-4 
FGlu 2.11(0.87) 0.015 3.01(1.06) 5.0×10-3 2.47(0.67) 2.4×10-4 
DM 2.32(0.86) 7.1×10-3 3.11(1.07) 3.6×10-3 2.63(1.32) 8.7×10-5 
Multivariable 
model* 
1.45(1.04) 0.160 1.58(1.23) 0.200 1.50(0.79) 0.058 
*Including all quantitative potential confounders. 4 
†I2 = 0% in all meta-analyses5 
22 
 
Table 4. Mediation analysis to dissect the role of BMI in the %PC 38:3-PWD relationship. 
 MICROS ORCADES Meta-analysis 
 b(SE) P-value b(SE) P-value b(SE) P-value 
Does BMI mediate the PC 38:3%-PWD relationship? 
%PC 38:3  PWD* 2.27(0.86) 8.5×10-3 3.08(1.06) 1.9×10-3 2.59(0.67) 1.1×10-4 
%PC 38:3  BMI (1) 3.12(0.26) 1.0×10-33 3.49(0.28) 8.5×10-36 3.29(0.19) 7.3×10-67 
(%PC 38:3 | BMI)  PWD (Direct Effect) † 1.41(0.93) 0.131 1.50(1.14) 0.188 1.45(0.72) 0.045 
(BMI | %PC 38:3)  PWD (2) 0.25(0.12) 0.016 0.45(0.12) 2.0×10-4 0.35(0.08) 3.7×10-5 
Indirect Effect = (1)×(2) 0.78(0.38) 0.040‡ 1.57(0.44) 3×10-4‡ 1.12(0.29) 1.0×10-4 
Does %PC 38:3 mediate the BMI-PWD relationship? 
BMI  PWD 0.34(0.11) 0.001 0.51(0.11) 6.0×10-6 0.43(0.08) 4.7×10-8 
BMI  %PC 38:3 (1) 4.8×10-4(3.9×10-5) 1.2×10-33 4.0×10-4(3.2×10-5) 8.5×10-36 4.3×10-4(2.5×10-5) 2.4×10-68 
(BMI | %PC 38:3)  PWD (Direct Effect) 0.25(0.12) 0.016 0.45(0.12) 2.0×10-4 0.35(0.08) 3.7×10-5 
(%PC 38:3 | BMI)  PWD (2) 1.41(0.93) 0.131 1.50(1.14) 0.188 1.45(0.72) 0.045 
Indirect Effect = (1)×(2) 1.0×10-3(4.5×10-4) 0.133§  6.0×10-4(4.6×10-4) 0.191§ 8.0×10-4(4.5×10-4) 0.012 
Abbreviations: b: estimated association coefficient; SE: standard error. 
*Result reported in Table 2. 
†Result reported in Table 3. 
‡Sobel test P-values; corresponding bootstrap P-values: 0.04 (MICROS), 5×10-4 (ORCADES). 
§Sobel test P-values; corresponding bootstrap P-values: 0.111 (MICROS), 0.190 (ORCADES). 
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FIGURE LEGENDS 
 
Figure 1. Study flowchart. 
 
Figure 2. Pairwise comparisons between %PC 38:3, PWD, and BMI in MICROS and ORCADES, with marginal distributions. A) %PC 
38:3 vs PWD. B) %PC 38:3 vs BMI. C) BMI vs PWD. 
 
Figure 3. Mendelian randomization analyses. (A) Pathway: %PC 38:3  BMI  PWD. (B) Pathway: BMI  %PC 38:3  PWD. (C) 
Pathways: BMI  %PC 38:3 and BMI  PWD (BMI is a confounder). Abbreviations: p, P-value; R2tot, variance explained by all IVs; 
F, F-statistic; P-het, heterogeneity Q test’s P-value; b, effect estimate; SE, standard error. Heterogeneity summary statistics are reported 
for significant associations only. *5 studies: CHRIS, PREVEND, Lifelines, SHIP, and SHIP-TREND. Black and gray arrows are used 
to represent significant and non-significant causal associations, respectively. 
 
